Your browser doesn't support javascript.
loading
CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity
Yiru Long; Jianhua Sun; Tingting Liu; Feng Tang; Xinxin Zhang; Qiuping Qin; Yunqiu Miao; Xiaoyan Pan; Qi An; Mian Qin; Xiankun Tong; Xionghua Peng; Pan Yu; Peng Zhu; Weiliang Zhu; Yachun Zhang; Leike Zhang; Gengfu Xiao; Jianping Zuo; Wei Tang; Ji Zhou; Zhijian Xu; Yong Gan; Jin Ren; Wei Huang; Guangyi Jin; Likun Gong.
Affiliation
  • Yiru Long; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy
  • Jianhua Sun; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy
  • Tingting Liu; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Feng Tang; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy
  • Xinxin Zhang; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy
  • Qiuping Qin; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Yunqiu Miao; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy
  • Xiaoyan Pan; Wuhan institute of virology, Chinese academy of sciences
  • Qi An; Shanghai King-Cell Biotechnology Co., Ltd., No. 1136 Langong Road, Jinshan District, Shanghai
  • Mian Qin; Zhongshan Institute for Drug Discovery, Institutes of Drug Discovery and Development, Chinese Academy of Sciences, Zhongshan, 528400, China.
  • Xiankun Tong; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Xionghua Peng; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Pan Yu; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Peng Zhu; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Weiliang Zhu; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy
  • Yachun Zhang; Shanghai King-Cell Biotechnology Co., Ltd., No. 1136 Langong Road, Jinshan District, Shanghai
  • Leike Zhang; Wuhan Institute of Virology, Chinese Academy of Sciences
  • Gengfu Xiao; Chinese Academy of Sciences
  • Jianping Zuo; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy
  • Wei Tang; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy
  • Ji Zhou; School of Pharmaceutical Sciences, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, 518060, China; International Cancer Center, Nation
  • Zhijian Xu; Shanghai Institute of Materia Medica, Chinese Academy of Sciences
  • Yong Gan; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy
  • Jin Ren; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy
  • Wei Huang; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy
  • Guangyi Jin; School of Pharmaceutical Sciences, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, 518060, China; International Cancer Center, Nation-
  • Likun Gong; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy
Preprint in English | bioRxiv | ID: ppbiorxiv-439275
ABSTRACT
Safe, economical and effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to achieve adequate herd immunity and halt the pandemic. We have constructed a novel SARS-CoV-2 vaccine, CoVac501, which is a self-adjuvanting peptide vaccine conjugated with Toll-like receptor 7 (TLR7) agonists. The vaccine contains two immunodominant peptides screened from receptor-binding domain (RBD) and is fully chemically synthesized. And the vaccine has optimized nanoemulsion formulation, outstanding stability and safety. In non-human primates (NHPs), CoVac501 elicited high and persistent titers of RBD-specific and protective neutralizing antibodies (NAbs), which were also effective to RBD mutations. CoVac501 was found to elicit the increase of memory T cells, antigen-specific CD8+ T cell responses and Th1-biased CD4+ T cell immune responses in NHPs. More importantly, the sera from the immunized NHPs can prevent infection of live SARS-CoV-2 in vitro. One-Sentence SummaryA novel SARS-CoV-2 vaccine we developed, CoVac501, which is a fully chemically synthesized and self-adjuvanting peptides conjugated with TLR7 agonists, can induce high-efficient humoral and cellular immune responses against SARS-CoV-2.
License
cc_no
Full text: Available Collection: Preprints Database: bioRxiv Language: English Year: 2021 Document type: Preprint
Full text: Available Collection: Preprints Database: bioRxiv Language: English Year: 2021 Document type: Preprint
...